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Viral inhibitionHere, we review the current knowledge about viral derived membranotropic peptides, and we discuss how they
may be used for many therapeutic applications.While they have been initially discovered in viral fusion proteins
and have been involved in the mechanism of viral entry, it is now clear that their features and their mode of in-
teraction withmembrane bilayers can be exploited to design viral inhibitors as well as to favor delivery of cargos
across the cellmembrane and across the blood–brain barrier. The peptide gH625 has been extensively used for all
these purposes and provides a signiﬁcant contribution to theﬁeld.Wedescribe the roles of this sequence in order
to close the gap between the many functions that are now emerging for membranotropic peptides.
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Over the past few decades peptides have progressively achieved
increased value in drug design and pharmaceutical delivery. Moreover,
great interest has been dedicated to the identiﬁcation of peptides as
drug candidates. The number of peptides in thepharmaceutical industryniversity of Naples “Federico II”,
).is continuously growing and about 10% of the entire drugmarket is rep-
resented by peptide based drugs [1,2]. Bioactive peptides can be derived
from natural sources or can be discovered through rational engineering,
high-throughput screening, or structure-based design starting from de-
ﬁned protein regions [3]. Among the many peptides playing a relevant
role in biology, some show a high propensity for binding to lipid mem-
branes due to their simultaneous hydrophobic and amphipathic nature.
This class of hydrophobic peptides is characterized by the presence
of unusual conspicuous amounts of alanine and glycine residues and
sometimes also prolines. Such a degree of Ala/Gly content is uncommon
Fig. 1. The conformational ﬂexibility of membranotropic peptides.
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anchors; in fact, their presence may account for the intrinsic conforma-
tional ﬂexibility which is a typical feature of membrane interacting
peptides.
Also aromatic residues are generally present anddominate the inter-
actions that take place at this unique physical–chemical environment of
the water–membrane interface [4]. The favorable interactions of aro-
matic side chains with phospholipid moieties located at the membrane
interface contribute to the insertion of the peptide into the bilayer.
Amphipathicity is a key feature of these peptides. The term
amphipathicity generally refers to molecules with both hydrophilic
and hydrophobic faces [5]. Peptides can be amphipathic in their primary
structure or secondary structure. Primary amphipathic peptides corre-
spond to the sequential assembly of a domain of hydrophobic residues
with a domain of hydrophilic residues divided by a spacer domain;
while secondary amphipathic peptides are generated by the conforma-
tional state which allows positioning of hydrophobic and hydrophilic
residues on opposite sides of the same molecule. In particular,
amphipathic, hydrophobic peptides present one face with large and
aromatic residues and the other with small residues such as Ala/Gly.
This distribution of amino acid residues facilitates the membrane
interaction and peptide insertion into the bilayer [6].
Conformational polymorphism plays a key role; in fact, the ability to
shift from random toα/β conformations as a consequence ofmembrane
composition and peptide concentration has emerged as a common
structural pattern for this class of peptides [6].
There are several types of membrane active peptides which can be
roughly divided in antimicrobial peptides [7], viral peptides [8] and
cell penetrating peptides [9]. Although very different in primary
sequence one from the other, it may be hypothesized that their com-
mon physical features could result in a shared mechanism of action
and essentially determines the many roles that they can play in nature.
Among the hydrophobic peptides with a propensity for membrane
binding, characterized by a high interfacial hydrophobicity or
amphipathicity, the ones derived from enveloped virus glycoproteins
are attracting considerable attention. These peptides can interfere
with enveloped virus entry by direct physical interaction with the
hydrophobic surfaces present on membranes and/or fusion proteins
and are, thus, critical for both fusion and entry.
Viral glycoproteins undergo conformational changes as a conse-
quence of either low endosomal pH or receptor binding which leads
to the exposure of hydrophobic peptides, loops or patches, which then
interact with and destabilize one or both the opposing membranes.
Crystallographic data on the post-fusion structures of viral fusion pro-
teins have allowed the identiﬁcation and characterization of three
different classes [10,11]. Class I fusion proteins are characterized by tri-
mers of hairpins with a central α-helical coiled-coil structure and have
been identiﬁed in orthomyxoviruses, paramyxoviruses, retroviruses,
ﬁloviruses and coronaviruses [12–16]. Class II fusion proteins are
present on viral envelopes as pre-fusion dimers which convert into
post-fusion trimers of hairpins composed of β structures and have
main representatives in the Flaviviridae and Togaviridae families
[17,18]. Class III fusion proteins are characterized by a central α-helical
trimeric core similar to Class I and two fusion loops located at the tip of
an elongated β-sheet similar to Class II fusion proteins and members
are present in Herpesviridae and Rhabdoviridae families [19].
Despite several differences in themechanism of entry elicited by the
three classes of fusion glycoproteins, they all induce membrane fusion
in a similar manner through the formation of an analogous hairpin
structure which allows fusion peptides to insert into cell membranes
and to drivemembrane destabilization. Thus, during the viral entry pro-
cess, the hydrophobic surfaces that become exposed are characterized
by somewhat variable but at the same time detailed physical character-
istics which include the size, shape and secondary structure of exposed
hydrophobic patches, as well as the nature of the neighboring polar or
charged residues.2. Membranotropic peptides and fusion ability
The Wimley–White interfacial hydrophobicity scale (WWIHS) is an
experimentally-determined free energy scale that calculates the pro-
pensity of individual amino acids in peptide sequences to partition
from water into a phosphatidylcholine interface [20,21] and has been
effectively used to identify fusion peptides in viral glycoproteins. The
hydropathy analysis allows calculating a hydrophobicity score along
the sequence of a protein, identifying segments with a propensity to
interact with membrane interfaces. WWIHS values are calculated as-
suming random coil peptides partitioned into the bilayer interface; the
values areminimumpossible values and theΔGmay getmore favorable
if peptide binding also promotes an increase in secondary structure
[22,23].
The interfacial helical hydrophobic moment (iHHM) is a further
physico-chemical factor that is important for membrane interactions
and secondary structure formation of peptides bound to membrane in-
terfaces. The iHHM describes the degree to which a peptide sequence
would have segregated hydrophobic and hydrophilic faces if it folded
into an α-helix [24]. A peptide with a large iHHM can interact strongly
with membranes as a helix due to partitioning–folding coupling
[22,23] even with a WWIHS score that is not positive overall.
The presence of the fusion peptide within the ectodomain exposed
to the aqueous phase is a feature shared by all viral fusion proteins
and constitutes an absolute requirement for their fusogenic activity. Fu-
sion peptides are typically 20–30 residues long and potentially fold into
amphipathic helices and are rich in glycines and alanines, providing
them a high degree of conformational ﬂexibility. Thus, their structure
is polymorphic and strongly dependent on the environment. The fusion
peptide of inﬂuenza virus, for example, has been observed in random
coil, α-helical and β-sheet conformations in different environments
[25] (Fig. 1).
It has been proposed that all three forms have some physiological
relevance; the peptide may be unstructured in solution on the way to
the target membrane; it may be helical at low concentrations but may
self-associate in β-sheets at higher concentrations in the membrane
interface. The fusion peptide of HIV also undergoes conformational
transitions; it adopts α helical or β sheet structures depending on con-
centration, lipids and ionic conditions [26].
The helical form of the inﬂuenza fusion peptide is probably a key de-
terminant to promote fusion. The structure of the peptide in membrane
shows a kink which separates the N terminal and the short C terminal
helices which together form a boomerang shaped structure [27]. Both
helical arms are amphipathic with bulky hydrophobic residues facing
the membrane interior. The conserved N-terminal glycine residue is
critical for fusion and for the correct structure of the peptide inside
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helix is partially unwound and the fusion peptide is inactive [28].
Actually, there are numerous studies demonstrating that a delicate
balance between α and β structures, is essential for membrane fusion
and is inﬂuenced by environmental conditions such as pH, ionic
strength, peptide sequence, presence or absence of divalent cations,
cholesterol content and also by the lipid/peptide ratio. For instance,
studies performed on the Ebola fusion peptide, show that the conforma-
tional transition from an α-helix to a β-sheet is induced by a change in
the peptide to lipid ratio in the membrane [29]. At low peptide concen-
tration in lipids, it is essentially an α-helix; while as the local peptide
concentration increases in the membrane, the proportion of α-helix
drops off in favor of amainly antiparallel β-sheet structure. This concen-
tration dependent effect on peptide conformationmight be of biological
relevance [29].
The functional meaning of the conformational polymorphism is
unclear, although it is believed to be fundamental to enable backbone
reorientation of the fusion protein; therefore, the ability to insert at
various levels might be required for the evolving of ﬁnal stages of the
fusion cascade [30]. Independently from the principal conformational
organization, the degree of insertion plays a key role for inducingmem-
brane fusion. It has also been hypothesized that [31] fusion domains
ﬁrst assemble as β-sheets on the surface of the membrane and later
convert into α-helices to complete fusion.
Aromatic residues are generally present in fusion peptides and may
help in overcoming the energy cost of peptide bond partitioning into
membranes. The interactions with phospholipid moieties located at
the membrane interfaces may also help in stabilizing the insertion
into just one leaﬂet of the bilayer. The initial interaction with the exter-
nal leaﬂet is thought to generate elastic stresses which drive to bilayer
fusion, helping to overcome the hydration repulsion forces between
approaching bilayers by orienting the poorly solvated face toward the
external medium [32]. The asymmetric insertion into one membrane
monolayer may promote expansion of the polar head region and deter-
mine a curvature stress onto the overall lipid bilayer; the created bulges
that protrude from the membrane can facilitate the formation of lipid
contacts between fusing bilayers [33].
Particular attention has also been devoted to the effect of additional
membranotropic sequences on the overall fusogenicity. The presence of
additional fusogenic sequences was evidenced in Sendai F1 [34], Mea-
sles F1 [35], SARS-CoV S2 [36], Hepatitic C virus E1 and E2 [37], Dengue
E [38,39] and Herpes Virus gB and gH [40–42]. The idea that a single
fusion peptide is the solely responsible for the complete membrane
fusion event has been substituted by the assumption that a concerted
action of different membranotropic regions is necessary for membrane
interacting/perturbing activity. As amatter of fact, alsomembrane prox-
imal regions (pre-TM) play a key role in fusion [41,43–45]. The pre-TM
domains are particularly rich in aromatic residueswhich enable them to
insert into the membrane interface.
3. Viral inhibition
Effective therapeutics against enveloped viruses are still scarcely
represented. A few drugs have been developed against HIV, inﬂuenza
virus, hepatitis virus and a few other viruses but they are still not ideal
and in some cases have proved to induce resistance [46]. As a conse-
quence, for most enveloped viruses, there are no effective therapies
and entry inhibitors represent an interesting and underutilized target.
Peptides with a propensity for membrane binding can also interfere
with enveloped virus entry by direct physical interaction with the
hydrophobic surfaces present on cell membranes and/or fusion pro-
teins. As recently reviewed by Badani et al. [46], there are many peptide
inhibitors that are somewhat hydrophobic and/or amphipathic with a
propensity to bind to bilayermembrane interfaces and other hydropho-
bic surfaces. It is not knownwhethermembrane binding directly affects
viral fusion, or whether interaction with the fusion protein itself is anabsolute requirement for entry inhibition. It is widely accepted that
membrane binding of an inhibitory peptide will greatly increase the
effective concentration of the peptide close to the fusion protein, indi-
cating that the interaction with membrane and the interaction with
the fusion protein may be effectively coupled [47].
As amatter of fact, the potential of numerous fusion peptides and/or
membranotropic peptides derived from proteins of enveloped viruses
as entry inhibitors has been widely described in literature [48–51].
The accepted view is that the inhibition of infectivity may be due to
the formation of inactive aggregates between the fusogenic stretches
present in both the viral protein and the synthetic peptides. These
aggregates are formed as a consequence of their ability to oligomerize
or tomimic themodes of binding of their original domains in their part-
ner protein. It has been hypothesized that they stabilize a pre-fusion
intermediate and prevent merging of the bilayers.
It is now evident that several domains are essential for membrane
fusion and thus peptides involved in the fusion mechanism may all
interfere with the intramolecular interactions between the several
domains and may represent interesting targets for the design of entry
inhibitors. Thus, membrane physical properties could be critically
important to the events that drive viral entry and it is conceivable that
peptides interfere with the function of viral fusion proteins by changing
the physical chemistry of the membrane itself by direct interaction.
Many laboratories are working to unravel the mechanism of action of
viral membranotropic peptides and several hypotheses have been
proposed. Many studies suggest that multiple mechanisms may take
place simultaneously. Indirect ways in which interfacial binding
peptides can affect viral entry have also been hypothesized. Self-
oligomerization of membrane embedded fusion peptides has been pro-
posed to be responsible of inhibition [52,53]. The most studied case is
that of HIV, where the inhibition has been attributed to the formation
of structurally deﬁned oligomeric complexes [54,55]; while mutants
with a lower helical content and tendency to self-associate into
β-sheets [56] are able to inhibit membrane fusion at various stages.
It is interesting to note that there are clinical studies on a peptide
called VIRIP, which is designed as an inhibitor of the HIV fusion peptide
[57,58]. This sequence was able to block HIV-1 infection by targeting
gp41 fusion peptide [58] and optimized versions of this sequence
proved to be as potent as inhibitors targeting the coiled coil sequences
and moreover were devoided of cellular toxicity. A 10-day monothera-
py clinical trial enrolling 18 HIV-1 infected patients [57] showed that
the drug can be well tolerated by patients and reduces their plasma
viral load. Its identiﬁcation and clinical evaluation represent the
ﬁrst proof of concept that membranotropic sequences could suppress
viral replication in infected individuals and have potential clinical
effectiveness.
The hypothesis that peptide entry inhibitors act by a physical–
chemical interaction with hydrophobic surfaces exposed during the
fusion process suggests that this novel approach may be a general rule;
moreover, instead of focussing on the structure-based design, it would
be possible to design novel hydrophobic/amphipathic inhibitors which
could be easily made protease resistant by the introduction of non-
natural or D-amino acids.
4. Delivery tools
The membrane bilayer represents a semi-permeable barrier, deﬁn-
ing the interior of an individual cell; its existence confers cells their
potential to survive and function properly. Nevertheless, crossing
of the cellular membranes remains one of the major obstacles for
the proper delivery of therapeutics [59,60]. The lipophilic nature of bio-
logical membranes restricts the direct intracellular delivery of most
compounds; whereas small molecules and ions can diffuse across the
bilayer, larger molecules are generally excluded from simple diffusion
into the cell. The differing hydrophobicity/hydrophilicity of the lipid
membrane renders the transfer across this barrier extremely difﬁcult
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tial of a number of novel molecules, their pharmaco-distribution prop-
erties hamper the possibility to reach the stage of pharmaceutical
preparations and stimulate industrial interest; in fact, these molecules
need to be delivered intracellularly to exert their therapeutic action
inside the cytoplasm or onto individual organelles. It is, thus, evident
that the therapeutic potential of a drug is largely dependent on the
development of delivery tools able to selectively and efﬁciently carry
it to target cells with minimal toxicity.
The translocation across the membrane is by far less well under-
stood than the binding step. There is a signiﬁcant similarity in the
physico-chemical parameters between membrane partitioning pep-
tides and membrane translocating peptides [61]. A novel intriguing hy-
pothesis is that hydrophobic peptides that partition into membranes
may also be able to cross cell membranes and enter cells. Therefore,
these peptides may also cross endothelial layers in vivo, including the
blood–brain barrier [62,63].
Delivery across cellular membranes involves several membrane
reorganization processes such as transient permeabilization of the
cell membrane, which are similar to the ones involved in the entry of
viruses. Membrane fusion and its disruption are related processes, al-
though leakage and fusion capacities of peptides donot always correlate
and the features/activities of membranotropic peptides may depend
on particular environmental and temporal conditions. Since not all
membranotropic peptides are able to cross the membrane bilayer, it is
essential to identify structural characteristics of hydrophobic peptides
know to enter the cell membrane to highlight any feature that is
involved in the penetrationwhichmay help in the design of novel deliv-
ery tools. Thus, an important feature to consider is the structural re-
quirements for cellular uptake and the ability of membranotropic
peptides to interact with the cell surface and lipid moieties of the cell
membrane. A very complete review describing the binding and translo-
cation of membrane active peptides has been recently published [64]
which highlights the fact that peptide translocation is not coupled
with dye ﬂux. Graded dye ﬂux would occur concomitant with peptide
translocation, which would explain incomplete dye release; whereas
all-or-none ﬂux would occur with peptides unable to translocate, and
therefore these peptides accumulate on the membrane until a rupture
point is reached, resulting in complete dye release [64].
Cell-penetrating peptides (CPPs) have beenwidely used due to their
capability to transport several kinds of macromolecules across the
membrane bilayer in vitro and in vivo [65–67]. CPPs are short and usu-
ally basic amino acid rich peptides originating from proteins that are
able to cross biological barriers, such as the viral TAT protein. Although
the uptake mechanism of CPPs is still debated, it seems to involve
mainly the endocytic pathway, trapping the conjugated cargo in
endosomes eventually ending in lysosomes where common enzymatic
degradation mechanisms take place, therefore leading to a limited
delivery of therapeutic agents to the intracellular target.
Hydrophobic peptides that efﬁciently traverse biological mem-
branes, promoting lipid-membrane reorganizing processes, such as
fusion or pore formation and involving temporary membrane destabili-
zation and subsequent reorganization [8,68], may be able to circumvent
the endosomal entrapment either favoring the escape from the endo-
some or by translocating a cargo through the plasmamembrane directly
into the cytosol.
This idea has been exploited to design the drug delivery tool called
MPG. MPG is an amphipathic peptide whose primary sequence is com-
posed of the hydrophobic amino acids of the HIV-1 fusion peptide
(GALFLGFLGAAGSTMGA) associated to a hydrophilic domain derived
from the Nuclear Localization Sequence (NLS) of Simian virus 40 (SV40)
large T antigen (PKKKRKV). These hydrophilic and hydrophobic seg-
ments are separated by a three amino-acid spacer (WSQ) [69,70]. This
peptide exploits the knownproperties of the glycine-rich HIV fusion pep-
tide essential for membrane fusion activity and the NLS of the SV40 large
T antigen to improve the nuclear addressing of the peptide [71,72].At the moment this is the only viral fusion peptide that has been
widely exploited for applications in drug delivery.
5. A case study: gH625, a membranotropic peptide derived from
Herpes simplex virus type I
Amilestone in understanding the role of hydrophobic viral peptides
is represented by the sequence “gH625” derived from glycoprotein H of
Herpes simplex virus type I. Herpes simplex virus (HSV) is an important
human pathogen, responsible for signiﬁcant morbidity and mortality
worldwide and is characterized by a complex multi-component entry
machinery. HSV enters host cells by fusion of the viral envelope with
either the plasma membrane or an endosomal membrane, and the
entry pathway is likely determined by both virus and host cell factors
and involves multiple viral glycoproteins and cellular receptors in a
cascade of molecular interactions [73–76]. The envelope glycoproteins
gH/gL, gB and gD are all essential for the entry process and their expres-
sion is able to induce the fusion of cellular membranes in a virus-free
system [77,78]. Both gH/gL and gB constitute the core fusionmachinery
and cooperate to induce the initial lipid destabilization that ends in
fusion [79] and both gB and gH contain several membranotropic se-
quences [40–42,49,50,80–82]. Although it has recently become avail-
able the crystal structure of the gH–gL complex [83], it is still debated
whether gH is merely a fusion regulator or it plays a more direct role
in the fusion process andmany studies suggest that the gH–gL complex
may undergo dynamic rearrangements [77,84]. In particular, some pep-
tides derived from the gH ectodomain block virus entry, while others
have the ability to bind and disruptmodelmembranes. gB is considered
a canonical Class III fusion protein and has been demonstrated to be
involved in virus attachment, penetration and cell-to-cell spread. The
crystal structure of gB is a trimer in which multiple contacts between
protomers throughout the molecule contribute to its stability [85]. It
has been hypothesized [86] that gB refolds similarly to Class I fusion
proteins and that the packing of the C-terminal arm against the
coiled-coil provides the driving force for gB refolding from the prefusion
to the post-fusion conformation. The gB structure corresponds to a post
fusion conformation and it is now widely accepted that gB undergoes
conformational changes upon variations of pH in order to bring about
fusion [87–90]. Several synthetic gB peptides induced the fusion of
large unilamellar vesicles and inhibited herpes virus infection [42,91].
When the crystal structures of gB and of gH/gLwere not yet available,
we reported the identiﬁcation of several sequences in gH and gBwith the
ability to interact with the membrane and among these sequences there
was also the canonical fusion peptide of gB [40,42,80,92]. Although it is
not yetwell understood the role playedby the othermembranotropic se-
quences and in particular by the glycoprotein gH in thewhole fusion pro-
cess, it is now widely accepted that several regions in the fusion
glycoproteins are involved in the local destabilization of the membrane
bilayer which ends in the fusion of the viral envelope with the host cell
membrane.
gH625wasﬁrst selected and characterized by our group in 2005 [40]
and still is the HSV-1 peptide with the highest fusion capability and the
most widely studied. It was initially identiﬁed using the WWIH scale
and subsequent works allowed determining the many applications of
this sequence from membrane fusion, to viral inhibition and drug
delivery [63,93,94].
5.1. General features and membrane interactions
The twenty residue peptide gH625 (from aa 625 to aa 644) is a
membrane-perturbing domain, (Fig. 2) which interacts with biological
membranes and is implicated in the merging of the viral envelope and
the cellular membrane [42,50]. The peptide contains residues crucial
for its capacity to interact and destabilize target lipid membranes. It is
rich in hydrophobic residues including glycines, leucines, alanines, and
aromatic residues such as tryptophan and tyrosines, which are known
Fig. 2. The many features of gH625: A) helical wheel representation of gH625; B) WWIHS hydrophobicity plot of the glycoprotein gH showing the peak corresponding to gH625;
C) peptide-promoted membrane fusion of PC/Chol (1:1) LUVs as determined by lipid mixing; D) toxicity assays performed on gH625 up to a concentration of 400 μM.
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lipid interactions are initiated by the arginine residue located at the
C-terminus; in fact, when the arginine is mutated, the fusogenic activity
of the peptide is strongly impaired. The hydrophobic domain is also
crucial for its insertion into the membrane and further supports the
view that hydrophobic interactions between fusion proteins and cell-
membrane phospholipids initiate membrane perturbation in the early
stages of viral fusion. The many biophysical experiments performed
on gH625 have shown that the peptide interacts with model mem-
branes, penetrates the bilayer from its N-terminal side, has a tryptophan
residue buried inside the bilayer, and adopts a helical conformation
with its hydrophobic residues on one face of the helix and polar or
charged residues on the opposite face [40,49,50].
The analysis of peptides with longer and shorter sequences derived
from this region and of their interactions withmembranes clearly dem-
onstrated that the activity of this region depends on the amino acid
sequence and on its length. The presence of a histidine residue at the
N-terminus of the native sequence strongly increases the fusion activity
[50]. The importance of a single histidine residue as a switch for trigger-
ing viral fusion was also reported for other viruses [95] such as para-
myxoviruses, therefore supporting the importance and speciﬁcity of
the histidine moiety in activating fusion. Furthermore, a conserved
histidine in one of the fusion loops of Semliki Forest virus E1 protein
was found to be fundamental [96]. The histidine in gH625 both helpsthe initial interactions with the membrane and the oligomerization
process [50]. This hypothesis is further supported by the fact that the
histidine is located at the N-terminus and correct conﬁguration of the
N-terminal fusion peptide appears to be crucial for the fusogenic function
of several fusion proteins as well as its location in the membrane core
after peptide-bilayer interaction. The addition of one histidine at the
N-terminus of gH625 is sufﬁcient to make the peptide approximatively
8-fold more active. In particular, the addition of any other residue at
the N-terminus impaired the fusion ability of the sequence (data not
published).
gH625 strongly interacts and spontaneously penetrates the
lipid-phase and inserts into membranes with a α-helical struc-
ture [50,81,82]. Both the tryptophan and tyrosine are on the same
side of the helix in the three-dimensional structure, forming an amphi-
philic helix in which one side is constituted by aromatic and hydropho-
bic residues, whereas the other side is formed by hydrophilic or small
residues. The interaction between the aromatic ring of tryptophan and
the side chain of tyrosine is important for maintenance of structural
stability during the interaction with the membrane. An amphipathic
α-helix is believed to be an important feature of membranotropic
peptides playing a crucial role for mediating lipid–protein interactions
during the binding of proteins to membranes and once bound, the
hydrophobic face of the amphipathic peptide would allow the peptide
to enter the membrane interior, thereby triggering local fusion of the
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fusion.
gH625 has the ability to penetrate deep into the bilayer as a helix
without causing signiﬁcant bilayer perturbations which may help
explaining its ability to perform several different roles.5.2. Viral inhibition
gH625 showed a signiﬁcant inhibitory effect and this effect appears
conditioned by its ability to partition into membranes and aggregate
within them. Since the peptide self-associates in aqueous and lipid solu-
tions, it is possible that it binds to its counterpart in the gH protein.
gH625 may also interact with the host cell membrane, therefore its
ability to moderately inhibit viral entry when cells are treated ﬁrst, is
dependent on the possibility that the virus will ﬁnd a modiﬁed cell
membrane still exhibiting on its surface the peptide [48]. Moreover,
gH625 does not have any activity in virus preincubation experiments,
indicating that an eventual binding partner site on the pre-fusion gH
protein is probably hidden and not available to interactions with free
peptides, as also demonstrated by the analysis of the gH crystallographic
structure.
While the N-terminal histidine residue was proven to be fundamen-
tal for the interaction with the membrane bilayer and for translocation
across themembrane, the absence of this residue induced similar levels
of viral inhibition when compared with the full length peptide. The
substitution of Leu627 with a valine residue does not alter the hydro-
phobicity of the peptide, and does not inﬂuence its infectivity inhibition
properties while its substitution with a polar residue (serine) substan-
tially reduces its inhibitory activity [49].
Recently, poly(amide)-based dendrimers functionalized at their
termini with gH625 were shown to inhibit both HSV-1 and HSV-2 at a
very early stage of the entry process, most likely through an interaction
with the viral envelope glycoproteins; thus, preventing the virus from
coming into close contact with cellular membranes, a prerequisite
for viral internalization [97]. The 50% inhibitory concentration was
100 and 300 nM against HSV-1 and HSV-2 respectively, with no
evidence of cell toxicity at these concentrations, indicating that the
functionalization of a dendrimerwith amembranotropic peptide repre-
sents a promising strategy for inhibition of viruses of the Herpesviridae
family. The multivalent display of gH625 on the dendrimer scaffold
results in an almost six fold increase of antiviral activity for HSV-1
and two fold for HSV-2 in comparison to the activity of the dendrimer
itself, and more than 100-fold increase in the activity of the unsupport-
ed peptide. The cytotoxicity proﬁle measured by theMTT assay showed
that the peptidodendrimer is not toxic to Vero cells up to the highest
concentration investigated in antiviral testing, while some toxicity
was observed for the unfunctionalized dendrimer, especially at higher
concentrations, demonstrating another advantage of the peptide
functionalization [97]. Any inhibitory activity was excluded when the
compounds were added at a post-entry step and also when cells were
pre-treated with the dendrimer derivatives, indicating that both the
peptidodendrimer and the dendrimer are not able to interfere with
viral replication once the virus has gained access to the cellular milieu.
The peptidodendrimer might sterically hinder the gH relative domain,
either in a pre-fusogenic or in an intermediate conformation,
preventing a complete and functional interaction between gH and the
membrane to fuse. The mechanism of inhibition may involve binding
to gH itself through oligomerization of the gH625 domain present on
the glycoprotein or interaction with other glycoproteins present on
the virion envelope, such as gB or gD.
Themodiﬁcation of a dendrimer scaffoldwithmembranotropic pep-
tides represents an attractive strategy for the design of a new class of
antiviral drugs that exert their effect, coupling the intrinsic anti-viral
properties of the dendrimer with the activity of membranotropic pep-
tides and have the potential of being developed as multifunctionalizedscaffolds to provide a therapeutic molecule to directly deliver to its
target [97].
The inhibition ofmembrane fusion represents an attractive target for
drug design and although further studies are needed to better deﬁne the
exactmechanismof inhibition by hydrophobic peptides and the speciﬁc
nature or location of their interactions with viral targets, the data ob-
tained for gH625 suggest that hydrophobic domains play a signiﬁcant
role inmembrane fusion and provide an alternative approach to the de-
velopment of viral peptide inhibitors outside of the classical inhibitory
heptad repeat regions.
5.3. Applications to drug delivery
gH625 cellular uptake is associatedwith its hydrophobic and amphi-
pathic characters which provide the necessary ability to interact with
membrane lipids and to form a transient helical structure that tempo-
rarily affects membrane organization, thereby facilitating insertion
into the membrane and translocation [98].
Compared to TAT peptide (a positively charged CPP) which mainly
exploits the endocytic pathway, gH625 crosses membrane bilayers
mainly through a translocation mechanism. A one amino acid shorter
version of this fusogenic peptide was also found to improve the
endosomal release of DNA/Lipofectamine lipoplexes and transgene
expression up to 30-fold in human cell lines [99]. It has been recently
demonstrated that gH625 is able to traverse the membrane bilayer
and to transport into the cytosol several compounds, such as QDs [98],
liposomes [100], NPs [62], dendrimers [101], and proteins [102]. Exam-
ples of using gH625 as an intracellular delivery enhancer are provided in
the remaining part of the paragraph (Fig. 3).
QDs are ﬂuorescent probes under intense research and development
for broad applications in molecular, cellular and in vivo imaging [103].
Although considerable success has been achieved in usingQDs for label-
ing ﬁxed cells and for imaging cell membrane proteins, only limited
progress has been made for molecular imaging inside living cells
because of their insufﬁcient ability to traverse cell membranes. Several
authors have recently reported on the functionalization of QDs with
positively charged CPPs and established that themain route of entrance
is via endosomal uptake, therefore, escape from the endosomal system
is of paramount importance [104–106]. gH625-QD internalization was
demonstrated to be highly successful and to involve the endocytic path-
way only to a minor extent [98].
Liposomal aggregates have also attracted great attention due to their
success as in vivo carriers of drugs [107]. To enhance the antitumor efﬁ-
cacy of liposomal drugs, the efforts ofmany research groups are directed
toward the improvement of cellular internalization of liposomes
through the addition of surface ligands and cell penetrating peptides.
Liposomes decorated with gH625 and loaded with doxorubicin (Dox)
[100], were able to penetrate inside livingHeLa cells. The results obtain-
ed suggest that the functionalization of liposomes with gH625 could
affect the uptake mechanism of liposomes and their intracellular distri-
bution and Dox release. This evidence could be useful in the design of
carriers for a controlled delivery and release of Dox in order to avoid
side effects associated to Dox itself.
Dendrimers [108,109] also represent a very promising tool for drug
delivery, combining the advantageous features of nanoparticles
(ideal size as in vivo carriers, multivalency), of polymeric materials
(low cost, tunable properties, biocompatibility) and of small molecules
(monodispersity and detailed control of their properties) [109,110].
Their surface modiﬁcation by means of conjugation or adsorption of a
biospeciﬁc ligand,may allow their delivery to speciﬁc sites andmodula-
tion of drug releaseminimizing toxic effects and increasing intracellular
bioavailability [111]. Thus, the dendrimeric scaffolds may be a promis-
ing tool for an efﬁcient drug delivery engine. Little information is
available on the mechanism of dendrimer uptake and intracellular
trafﬁcking [112]. Studies performed on PAMAM dendrimers [113] and
PAMAM dendrimers functionalized with the TAT [114] indicate that
Fig. 3. Themany applications of gH625 to drug delivery. Confocal microscopy images showing the internalization of gH625 functionalized: A) proteins [102]; B) liposomes [100]; C) Qdots
[98]; D) dendrimers [101]. E) Scanning electron microscopy images of functionalized polystyrene nanoparticles [62].
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lular trafﬁcking and that adding the TAT failed to enhance delivery efﬁ-
ciency. The attachment of gH625 to the termini of a poly(amide)-based
dendrimer allows the conjugate to penetrate into the cellular matrix,
whereas the unfunctionalized dendrimer is excluded from transloca-
tion. The peptide-functionalized dendrimer is rapidly taken into the
cells mainly through a non-active translocation mechanism [101]. The
combination of the beneﬁts of dendrimers and peptides chemistry
could be useful for the development of a selective carrier which could
cross the membrane and be efﬁciently internalized into the cellular
targets.
5.4. In vitro and in vivo delivery across the blood–brain barrier
Many therapeutic drugs are excluded from entering the brain, due to
their lack of transport through the blood–brain-barrier (BBB) [115]. The
development of new strategies for enhancing drug delivery to the brain
is fundamental in diagnostics and therapeutics of central nervous
diseases (CNS). Most strategies to transport drugs inside the CNS
cause disruption of the anatomical texture of the BBB, therefore
impairing its natural function; as a consequence, effective delivery
approaches should be cautiously assessed considering their impact on
the overall protective function of the BBB [116]. Targeted delivery of a
therapeutic cargo to the intended site of action in the brain appears tobe one of the most promising non-invasive approach to overcome the
BBB, combining the advantages of brain targeting, high incorporation
capacity, reduction of side effects and circumvention of the multidrug
efﬂux system [117–120].
Polystyrene nanoparticles (NPs) decorated on their surface by
gH625 showed that the uptake of NPs with gH625 by brain endothelial
cells was greater than that of the NPs without the peptide and function-
alized NPs were free to move intracellularly [62]. Most importantly,
gH625 decreased NP intracellular accumulation as large aggregates
and enhanced the NP BBB crossing. The surface functionalization with
gH625may change NPs fate and provides a good strategy for the design
of promising carriers to deliver drugs across the BBB for the treatment of
brain diseases.
Whethermultifunctional nanosystems, designed and tested in vitro,
are able to properly work in vivo into mammalian hosts, is not
fully granted. To address this issue, in vivo studies are necessary, thus
validating design strategies and facilitating optimization and further
functionalization. Although numerous studies showed that gH625 is
an efﬁcient carrier for bioactive cargoes in vitro [121], these results did
not guarantee that it can be developed into a useful pharmaceutical de-
livery platform. The ability of gH625 to cross the BBB in vivowas also re-
cently evaluated [122]. gH625 was administered in vivo to rats and its
presence in the liver and in the brain was detected. Within 3.5 h from
its i.v. administration, gH625 can be found beyond the BBB in proximity
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brain maximal oxidative capacity and mitochondrial respiration rate.
The data suggest that gH625, for its ability to cross the BBB, represents
a novel nano-carrier system for drug delivery to the central nervous sys-
tem. These results open new possibilities for direct delivery of drugs
into patients in the context of theranostics and might address the treat-
ment of several human diseases.
Other peptides have been proposed as a drug delivery system; it
was demonstrated that TAT was able to enter tissues in vivo in mice
[123]; ANTP was able to activate endogenous T cells in mice [124].
These peptides are highly positively charged, and absorptive-mediated
transcytosis has been proposed for their transport across the BBB. A bra-
dykinin analogue has also been reported to increase the penetration of
small molecules by transitory opening of the BBB [125]. gH625 is the
ﬁrst viral membranotropic peptide which was shown to be a potential
delivery system for macromolecules in vivo; these results coupled
with previous in vitro data support the view that gH625 enters the
BBB without involving endocytic processes. Hence, the eventual cargo
may be immediately and completely available [122].
The presence ofmultiplemetabolic barriersmay restrict the applica-
tion of such peptide-based ligand for targeted drug delivery in vivo.
Peptides alone or conjugated on the surface of nanocarriers are subject
to proteolysis in the blood after systemic administration. In addition, the
BBB is also ametabolic barrier due to the presence of various enzymes in
brain capillary endothelial cells. gH625 starts to be degraded after 1 h of
incubation but the intact peptide is still present after 3.5 h of incubation
and thus holds the potential for extending brain targeting efﬁciency due
to its resistance to proteolysis for 3.5 h [122].6. Conclusions
It is still under-recognized that some amino acid sequences in virtue
of their speciﬁc features can play many different roles in nature.
Membranotropic viral peptides derived from fusion glycoproteins are
widely studied especially for their ability to fuse membranes but there
are many literature data also describing other roles besides membrane
fusion. gH625 is an example of how these sequences can be employed
for completely different purposes: fusion of membranes, viral inhibition
and drug delivery. Till now, gH625 is the only membranotropic peptide
that has been extensively used for many applications and among them
as a drug delivery system for the brain. In the development of new ther-
apies to treat brain pathologies, the BBB represents a major obstacle
against the use of potential drugs for treating disorders of the CNS due
to the impermeable nature of the cell membranes of this compartment
to severalmolecules [115,126]. The data reported on the in vivo applica-
tion of gH625 for brain delivery, support the novel view that synthetic
peptides derived from viral membranotropic sequences can be used
successfully to deliver biologically active substances inside the BBB.
The exact molecular mechanism of gH625 entry remains to be
established but it appears to be a general feature of membranotropic
peptides, which may be used for mediating delivery to virtually any
tissue and in particular across the BBB, conveying a wide variety of
cargoes with intact bioactivity into virtually any tissue or organ. Other
sequences have been found to be useful for drug delivery which
happens to have the same features of the viral fusion peptide, indicating
that it may be possible to design novel sequences with pre-determined
characteristics which can be useful to treat many diseases.
However, stillmuchwork has to bedone on this type of peptides;we
should not forget that their mechanism of perturbation of membrane
bilayers may also allow the design of new membranotropic peptides
with the ability to denature the membrane bilayer of bacteria and
thus we may add to their many roles also the antibacterial activity
which may represent an alternative to classical antibiotics in order to
combat the antibiotic resistance problem. Much of the vast literature
on membranotropic peptides is devoted to single activities of thesesequences; yet compelling structure–function relationship studies
bridging the gap among all these activities are necessary.
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